Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21315832 | 1.00 | SIGMAR1 (0.54) | SIGMAR1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL31421211 | 0.88 | SIGMAR1 (0.48) | SIGMAR1LMNAALDH1A1 | |
| SCHEMBL22287239 | 0.86 | MAPT (0.42) | SIGMAR1 | |
| SCHEMBL30662447 | 0.86 | SIGMAR1 (0.52) | SIGMAR1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL30662450 | 0.86 | SIGMAR1 (0.52) | SIGMAR1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL7240012 | 0.83 | SIGMAR1 (0.58) | SIGMAR1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL21315846 | 0.81 | SIGMAR1 (0.59) | SIGMAR1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL17154964 | 0.81 | GBA1 (0.44) | SIGMAR1 | |
| SCHEMBL124097 | 0.81 | SIGMAR1 (0.59) | SIGMAR1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL31421387 | 0.81 | DRD4 (0.44) | SIGMAR1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900666-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Ignyta, Inc. (US) | 2015-08-05 | — | — | EP | claimed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | claimed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-114805311-B | Spirocyclic indenes | 苏州亚盛药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240216361-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2023226900-A1 | 2-(PIPERAZINE-2-YL) ACETONITRILE DERIVATIVE, PREPARATION METHOD FOR, AND USE THEREOF | 苏州泽璟生物制药股份有限公司 | 2023-11-30 | — | — | WO | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-8093237-B2 | 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds; psychological disorders, sleep disorders; antipsychotic agents that modulate monoaminergic neurotransmitter receptor subtypes; side effect reduction | ARYX THERAPEUTICS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | PROTOCELL THERAPEUTICS INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | PROTOCELL THERAPEUTICS INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | PROTOCELL THERAPEUTICS INC. | 2008-10-16 | — | — | US | disclosed |
| WO-2008112900-A1 | DIBENZO[B,F][1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| EP-0638568-B1 | Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them | ADIR (FR) | 1996-10-09 | — | — | EP | disclosed |
| US-5500426-A | ADMINISTERED TO IMPROVE GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-03-19 | — | — | US | disclosed |
| US-5492912-A | IMPROVES GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-02-20 | — | — | US | disclosed |
| EP-0638568-A1 | Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216361-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | SIGMAR1 1215/4885LMNA 2990/4885ALDH1A1 167/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SIGMAR1 4812/4885LMNA 2991/4885ALDH1A1 3370/4885 |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | SIGMAR1 1180/4885LMNA 3338/4885ALDH1A1 668/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SIGMAR1 4812/4885LMNA 2991/4885ALDH1A1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.